Evidence map›Paper›PMID 38455594›Full record

ArticleJTO clinical and research reports2024

Initial Safety and Feasibility Results From a Phase 1, Diagnose-and-Treat Trial of Neoadjuvant Intratumoral Cisplatin for Stage IV NSCLC.

Farrah B Khan, Pamela C Gibson, Scott Anderson, Sarah Wagner, Bernard F Cole, Peter Kaufman, C Matthew Kinsey

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JTO clinical and research reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Farrah B KhanDivision of Hematology and Oncology, Larner College of Medicine at the University of Vermont, Burlington, Vermont.
Pamela C GibsonDepartment of Pathology & Laboratory Medicine, Larner College of Medicine at the University of Vermont, Burlington, Vermont.
Scott AndersonDepartment of Pathology & Laboratory Medicine, University of Vermont College of Medicine, Burlington, Vermont.
Sarah WagnerDivision of Pulmonary and Critical Care, Larner College of Medicine at the University of Vermont, Burlington, Vermont.
Bernard F ColeDepartment of Mathematics and Statistics, University of Vermont, Burlington, Vermont.
Peter KaufmanDivision of Hematology and Oncology, Larner College of Medicine at the University of Vermont, Burlington, Vermont.
C Matthew KinseyDivision of Pulmonary and Critical Care, Larner College of Medicine at the University of Vermont, Burlington, Vermont.
University of Vermont · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neoadjuvant intratumoral cisplatin has the potential to generate substantial cytotoxicity and immune priming within the tumor environment, while minimizing systemic, off-target, adverse events. We initiated a phase 1A, 3+3 dose-ranging study of neoadjuvant, intratumoral cisplatin, delivered through endobronchial ultrasound bronchoscopy, in the same procedure as the initial diagnosis. There were no dose-limiting toxicity identified at the 20mg level.

Indexed as

CisplatinEndobronchial ultrasound-guided transbronchial needle injectionIntratumoral therapyLung cancer

Identifiers

PMID38455594
PMCPMC10918561
OpenAlexW4390837093

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.